Aspyra (OTCMKTS:APYI) vs. SOPHiA GENETICS (NASDAQ:SOPH) Financial Comparison

Aspyra (OTCMKTS:APYI) and SOPHiA GENETICS (NASDAQ:SOPH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Earnings and Valuation

This table compares Aspyra and SOPHiA GENETICS”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspyra	N/A	N/A	N/A	N/A	N/A
SOPHiA GENETICS	$77.27 million	4.47	-$79.00 million	($0.51)	-9.88

Aspyra has higher earnings, but lower revenue than SOPHiA GENETICS.

Risk and Volatility

Aspyra has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Aspyra and SOPHiA GENETICS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspyra	0	0	0	0	0.00
SOPHiA GENETICS	1	0	2	0	2.33

SOPHiA GENETICS has a consensus price target of $7.00, indicating a potential upside of 38.89%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Aspyra.

Profitability

This table compares Aspyra and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspyra	N/A	N/A	N/A
SOPHiA GENETICS	-44.22%	-50.60%	-21.00%

Institutional & Insider Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 23.9% of Aspyra shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

SOPHiA GENETICS beats Aspyra on 6 of the 10 factors compared between the two stocks.

About Aspyra

Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.